<DOC>
	<DOCNO>NCT02298075</DOCNO>
	<brief_summary>The primary objective study evaluation sustain response rate discontinuation treatment TPO-RAs , Eltrombopag Romiplostim , persistent chronic pITP patient fail one therapy line , splenectomy include .</brief_summary>
	<brief_title>Response Rate Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia</brief_title>
	<detailed_description>Increasing evidence exist literature persistent response TPO-RAs discontinuation . However , available data consist description case report different patient ' series . At time , systematic data collection topic exist real incidence persistent response unknown . Therefore , increase interest new challenge therapeutic field , also therapeutic implication , would like investigate impact TPO- RAs achievement sustain persistent response discontinuation Italian adult patient affect pITP referred GIMEMA Centers .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Signed write informed consent accord ICH/EU/GCP national local law ; Persistent chronic pITP adult patient treat TPORAs therapy failure one therapy line , splenectomy include ; Age &gt; 18 year . Active malignancy ; Active malignancy ; HCVAb , HIVAb , HBsAg , HBcAb seropositive status ; Chronic liver disease ; Treatment Rituximab le 8 week TPORAs start ; Recent splenectomy ( le 8 week ) TPORAs start . Active malignancy ; HCVAb , HIVAb , HBsAg , HBcAb seropositive status ; Chronic liver disease ; Treatment Rituximab le 8 week TPORAs start ; Recent splenectomy ( le 8 week ) TPORAs start . HCVAb , HIVAb , HBsAg , HBcAb seropositive status ; Chronic liver disease ; Treatment Rituximab le 8 week TPORAs start ; Recent splenectomy ( le 8 week ) TPORAs start .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Immune thrombocytopenia</keyword>
	<keyword>Primary</keyword>
	<keyword>Thrombopoietin receptor agonist</keyword>
</DOC>